The Diagnostic Value of Neutrophil to Lymphocyte Ratio as an Effective Biomarker for Eye Disorders: A Meta-Analysis

Table 1

Characteristic of included studies.

Author	Year	Country	Exclusion criteria based on medication taking history	Patients with eye diseases			Healthy controls			Quality
				Number	NLR		Number	NLR
					Mean	SD		Mean	SD
Keratoconus
Karaca	2014	Turkey	Smoking habit, current anti-inflammatory therapies	54	2.59	0.89	25	1.86	0.52	Moderate
Katipoglu	2019	Turkey	Anti-hyperlipidemic therapy or steroid use, or smoking and alcohol use	31	2.30	0.80	31	1.70	0.60	Low
Bozkurt	2020	Turkey	ND	35	2.01	0.53	30	1.97	0.41	Moderate
Elbeyli	2021	Turkey	Anti-hyperlipidemic therapy or steroid use, or smoking and alcohol use, current anti-inflammatory therapies	42	2.50	0.80	42	1.70	0.30	Low
Oltutu	2021	Turkey	Smoker, and alcohol abuse, any medication that could affect blood parameters	43	2.30	0.87	43	1.77	0.61	Critical
Reyhan	2021	Turkey	Currently receiving anti-inflammatory drugs, smoking, and alcohol use	40	2.15	1.46	40	1.81	0.72	Moderate
Dry eye disease
Sekeryap	2016	Turkey	Smoking, taking anti-inflammatory drugs	33	2.80	1.40	32	1.60	0.70	Low
Celic	2017	Turkey	Smoking, receiving ocular/systemic drug	78	1.84	0.50	60	2.60	1.20	Moderate
Ozcan	2020	Turkey	Smoking, systemic or ocular medications including topical steroids (the previous use during at least 3 months) and anti-inflammatory medications, that could affect the ocular surface of the eye and blood parameters	47	2.26	0.55	47	1.81	0.55	Moderate
Meng	2021	China	Receiving hormone medication and systemic or tropical immunosuppressant during three months	104	2.59	1.25	97	2.20	1.24	Moderate
Pterygium
Akcam	2019	Turkey	Receiving topical/systemic drug, cigarette/alcohol using	30	1.86	0.38	31	1.76	0.54	Moderate
Atilgan	2019	Turkey	Steroid use	200	2.10	0.89	200	2.05	0.80	Low
Gokmen	2019	Turkey	Smoking, using steroid, or oral contraceptive drugs	111	2.53	2.27	106	2.04	1.03	Low
Kilic 1	2019	Turkey	Receiving antioxidant or anti-inflammatory medications or any topical or systemic drugs	71	1.90	0.59	46	1.73	0.67	Moderate
Kurtul2	2019	Turkey	Receiving immunosuppressive treatment	61	1.85	0.82	55	2.72	0.79	Low
Kilic 2	2020	Turkey	Past systemic medical therapy, smoking	35	2.72	3.61	30	1.81	3.97	Low
Idiopathic epiretinal membrane
Dilkaya	2017	Turkey	Any special drug use (e.g., corticosteroids iron preparations, vitamins, and chemotherapeutic agents)	43	3.03	1.20	46	1.77	0.70	Moderate
Cubuk	2020	Turkey	Any drug use	42	2.85	0.72	40	2.18	0.71	Moderate
Ulza	2020	Turkey	A history of systemic drug use	57	2.10	0.90	51	1.64	0.46	Low
Demir	2021	Turkey	Receiving medications affecting whole blood parameters such as corticosteroid and iron and chemotherapeutic	36	2.13	0.43	39	1.63	0.28	Low
Glaucoma
Arikan	2015	Turkey	ND	40	2.30	0.20	40	1.70	0.10	Low
Ozgonul1	2015	Turkey	ND	29	2.45	0.82	42	1.84	0.59	Low
Ozgonul2	2016	Turkey	Any special drug use (e.g., corticosteroids, iron preparations, vitamins, and chemotherapeutic agents)	84	2.33	0.90	80	1.98	0.73	Moderate
Li	2017	China	ND	771	2.85	1.94	770	1.98	0.86	Serious
Kurtul 1	2018	Turkey	ND	14	2.19	0.78	43	1.56	0.58	Moderate
Atalay	2019	Turkey	Smoking	28	1.82	0.68	27	2.21	0.84	Moderate
Tang	2019	China	Any special drug use (e.g., corticosteroids, iron preparations, vitamins, and chemotherapeutic agents)	240	2.59	1.40	300	2.08	1.05	Moderate
Zhang	2019	China	ND	59	2.07	0.88	84	2.73	1.30	Low
Demirtas	2021	Turkey	ND	22	3.82	4.28	71	4.04	6.47	Serious
Karahan	2021	Turkey	ND	200	5.40	9.28	100	3.00	4.91	Moderate
Bashir	2022	India	ND	40	2.06	0.48	80	1.49	0.67	Moderate
Oh	2022	Korea	History of ocular drug use except cataracts	41	1.94	0.60	100	1.70	0.56	Moderate

NLR: neutrophil to lymphocyte ratio; SD: standard deviation; ND: not declared.